Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference

3 years ago

BOSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing…

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

3 years ago

Eight Abstracts Demonstrate Progress of Prelude’s Differentiated PipelineWILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD),…

Shockwave Medical Completes Acquisition of Neovasc

3 years ago

SANTA CLARA, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer…

Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)

3 years ago

MINNEAPOLIS, April 11, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics…

Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference

3 years ago

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development…

electroCore Announces Remittance of Annual License Fee from Teijin for Certain Exclusive Rights in Japan

3 years ago

ROCKAWAY, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness…

Cleantech Blue-Zone Technologies Signs Agreement With Respirair Global

3 years ago

Blue-Zone to install its patented anesthetic capture technology in Respirair manufacturing facilityTORONTO, April 11, 2023 (GLOBE NEWSWIRE) -- Blue-Zone Technologies…

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

3 years ago

CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science…

Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients

3 years ago

DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable…

Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference

3 years ago

STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to…